- Mannatech Inc (NASDAQ: MTEX) reported a second-quarter FY22 sales decline of 17.7% year-on-year, to $35 million, compared to $42.5 million.
- The gross profit for the quarter declined 16.4% to $27.1 million.
- The operating expenses for the quarter fell 13.6% to $26.2 million.
- The operating margin was 2.4%, and operating income for the quarter rose 136% to $0.9 million.
- The company held $21.2 million in cash and equivalents as of June 30, 2022.
- EPS for the quarter was $0.34 versus $0.99 last year.
- Price action: MTEX shares closed lower by 2.48% at $20.09 on Friday.
Reported September 29. ‘FDA Grants First Marketing Authorization For A DNA Test To Assess Predisposition For Dozens Of Cancer Types’
https://www.fda.gov/news-events/press-announcements/fda-grants-first-marketing-authorization-dna-test-assess-predisposition-dozens-cancer-typesToday, the U.S. Food and Drug Administration granted de novo marketing
